Combined use of ultra-short acting β-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone

  title={Combined use of ultra-short acting $\beta$-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone},
  author={Joachim Boldt and Stephan Suttner},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2135 - 2147}
In patients with impaired myocardial contractility associated with downregulation of the β-receptors, compounds inhibiting phosphodiesterase (PDE) 3 may be useful to increase contractility. The PDE3 inhibitor enoximone has been shown to improve pump-function independent from the β-receptor pathway. A simultaneous decrease in ventricular preload and afterload by vasodilation has led to the term ‘inodilator’. Esmolol is the only available ultra-short acting intravenous β-blocking agent. Due to… Expand
Perioperative β blockade: the debate continues
Combined therapy with a β blocker and a type III phosphodiesterase inhibitor might be a promising approach for patients undergoing non-cardiac surgery in whom myocardial protection is necessary, but cardiac function is impaired. Expand
Massive ingestion of cardiac drugs: toxicokinetic aspects of digoxin and sotalol during hemofiltration
CVVH has little influence on the clearance of Fab-bound digoxin from the body and, in contrast, sotalol is efficiently cleared by CVVH. Expand
Weaning from inotropic support and concomitant beta‐blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis
Beta‐blockers improve the prognosis in heart failure (HF), but their introduction may seem impossible in patients dependent on inotropic support. However, many of these patients can be titrated onExpand
Electrochemical and direct C–H methylthiolation of electron-rich aromatics
The electrochemical-induced C–H methylthiolation of electron-rich aromatics has been accomplished via a three component cross-coupling strategy. Potassium thiocyanate (KSCN) as both the supportingExpand


The Prophylactic Use of the β-Blocker Esmolol in Combination with Phosphodiesterase III Inhibitor Enoximone in Elderly Cardiac Surgery Patients: Retracted
It is concluded that, in comparison to an untreated control, the prophylactic use of a combination of esmolol and enoximone in elderly patients undergoing cardiac surgery with cardiopulmonary bypass resulted in overall beneficial effects on postbypass hemodynamic status, organ function, inflammatory response, and endothelial integrity. Expand
Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients.
In a randomized study, the haemodynamic effects of the new phosphodiesterase-III-inhibitor, enoximone, were compared with dobutamine in acutely beta-adrenoceptor blocked patients, and systemic vascular resistance increased only in the dobutamines group. Expand
Combined phosphodiesterase inhibition and β-blockade in the GI104313, decreases ischemia-induced arrhythmias in the rat
It is demonstrated that, in rats, G1104313 induced a decrease in both incidence of arrhythmias and mortality which was not associated with changes in ventricular cyclic nucleotide content. Expand
Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: Improvement in hemodynamic and metabolic profile
In patients with congestive heart failure enoximone improves hemodynamics and, in most cases, it does not influence energetics, producing a more physiologic hemodynamic and metabolic profile. Expand
Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction.
Long-term treatment with both beta-blockers, as well as an ACE inhibitor, benefited the healing process in rats post-MI. Expand
Physiologic response to the inotropic and vasodilator properties of enoximone.
It is concluded that, enoximone produces a substantial increase in contractility, a relatively minor increase in heart rate, and a decrease in systemic vascular resistance, which leads to an improvement in the pumping function of the failing heart. Expand
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Compared with before beta-blocker therapy, metoprolol treatment decreased the magnitude of mean pulmonary artery pressure and pulmonary wedge pressure decline during dobutamine infusion and increased the cardiac index (CI) and stroke volume index (SVI) response to enoximone administration, without any effect on other hemodynamic parameters. Expand
Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat
It is demonstrated that pimobendan and zaprinast increased the incidence of dysrhythmias and the mortality rate, which was accompanied by an increase in the ventricular content of cGMP. Expand
Clinical Experience With Esmolol, A Short‐Acting Beta‐Adrenergic Blocker In Cardiac Arrhythmias and Myocardial Ischemia
Esmolol was well tolerated in patients infused for durations of up to 24 hours and in patients with conditions for which treatment with beta blockers is inappropriate, and offers excellent benefits as compared with the currently available beta‐adrenergic blockers in the treatment of critically ill patients. Expand
Pharmacology, mechanisms of action and uses of selective phosphodiesterase inhibitors.
This article reviews the selective phosphodiesterase inhibitors which have both inotropic and vasodilator activity and concludes that these drugs should not be considered as first-line treatment for heart failure. Expand